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Circulating memory T cells are heterogeneous in their tissue tropism. The skin-seeking
T cell subset expresses the cutaneous lymphocyte-associated antigen (CLA) on their
surface. CLA+ memory T cells not only migrate from blood to skin but also recirculate
between blood and skin. Studying CLA+ memory T cells in cutaneous diseases has
allowed a better understanding of immune-inflammatory mechanisms that take place.
The analysis of the phenotypical features of these cells, their antigen specificity, cytokine
production profile, and changes in relationship to clinical status and therapies among
other characteristics have led to the concept that they constitute peripheral cellular
biomarkers in T cell-mediated cutaneous conditions. CLA+ memory T cells are of
relevance in the pathogenesis of several cutaneous diseases, such as psoriasis (PSO),
atopic dermatitis, vitiligo, and drug-induced allergic reactions, to name a few. The
interaction of circulating CLA+ T cells with skin-resident cells has been investigated in
different ex vivo coculture models made out of clinical samples. Interestingly, microbes
that are present in the skin or related with human skin diseases are preferentially
recognized by CLA+ T cells. Thus, the interaction of Streptococcus pyogenes with
CLA+ T cells in PSO is providing novel concepts that help to understand disease
immunopathogenesis. The goal of this review is to present latest results in the field
of CLA+ T cells in T cell-mediated inflammatory skin diseases and their translational
relevance for human immunodermatology.
Keywords: skin-homing lymphocytes, cutaneous inflammation, CLA+ T cell, human, translational,
immunodermatology
de Jesús-Gil et al. CLA+ T Cells in Cutaneous Diseases
INTRODUCTION
The existence of a cutaneous immune system in humans was
postulated almost 50 years ago (1) and recently reformulated
(2). In order to understand the adaptive immune response
regionally, for those human memory T cells that belong to
the cutaneous immunity, a skin-specific cell marker would be
of great help. The cutaneous lymphocyte-associated antigen
(CLA) constitutes a relevant marker that identifies the subset of
memory T lymphocytes functionally related to skin physiology.
CLA was discovered in 1990 by serendipity as a cell surface
carbohydrate preferentially expressed by T cells present in
cutaneous inflamed tissues, but no other organs (3). Since then,
a comprehensive number of scientific evidence described in
humans support the role of CLA as a relevant marker to identify
skin-associated memory T cells involved in T cell-mediated
cutaneous inflammation, that provide translational information
in numerous different human skin diseases. CLA is more than
a mere cell surface carbohydrate (3), preferentially expressed on
CD45RO+ T cells, which binds to endothelial E-selectin and
mediates cell adhesion and transendothelial migration together
with other molecules such as lymphocyte function-associated
antigen-1 (LFA-1), very late activation antigen-4 (VLA-4), and
C–C chemokine receptor type 10 (CCR10) (4). CLA+ T
lymphocytes are found in circulation and in inflamed and healthy
skin but not infiltrating other non-cutaneous sites (3, 5). The
fact that some CLA+ T cells are found in circulation deserves
special attention due to the consequences of blocking LFA-1 in
patients with atopic dermatitis (AD) and psoriasis (PSO) (6, 7).
During treatment with efalizumab, patients present a circulating
lymphocytosis of CLA+ T cells. If the treatment is interrupted, a
flare in disease occurs. One explanation to this effect is that CLA+
T cells recirculate between blood and skin during cutaneous
inflammation. Blocking their extravasation through LFA-1 leads
to accumulation of those cells in blood, consequently when the
blockade is released the cells enter abruptly into lesions and
make flare. This mechanism of CLA+ T cell recirculation has
important implications for the translational relevance of studying
circulating CLA+ T cells in human inflammatory skin disorders
(Figure 1A). CLA+ memory T cells participate in pathological
mechanisms of inflammatory disorders by recognizing key
triggers of disease and producing cytokines that affect cells
of the skin. The phenotype of those cells can reflect clinical
status of the patients. The goal of this review is to update this
information on circulating CLA+ T cells in different human skin
inflammatory diseases.
PSORIASIS
In PSO, CLA+ T cells are contributing to understand the
pathological mechanisms from a translational point of view using
ex vivo studies with clinical samples. Although PSO is considered
to be triggered by cathelicidin (LL-37) (8) and interferon (IFN)-
alpha (9, 10), the translation of this mechanism into patients
is complex since anti-IFN-alpha (11), anti-IFN-gamma (12),
and anti-IL-22 do not induce clinical improvement, to name
a few clinically invalidated mechanisms. Streptococcus pyogenes
(S. pyogenes) infection is the best characterized clinically relevant
trigger of PSO in patients (13). The molecular mechanism that
links S. pyogenes and IL-17 response is starting to be clarified
in PSO (14). Only CLA+ memory T cells, but not CLA−,
preferentially respond to S. pyogenes in an autologous coculture
of T cells and cutaneous epidermal cells from patients with
PSO (15). Besides, patients with PSO who are negative for
antistreptolysin O (ASO) antibody present increases levels of
immunoglobulin (Ig) A, but not IgG, to S. pyogenes, which are
directly associated with CLA+ T–cell-dependent IL-17 response
to S. pyogenes in vitro (16). These results suggest that increased
exposure to S. pyogenes, as demonstrated by the presence of
specific humoral immune response even in patients with ASO
negative, upon recognition by CLA+ T cells can fuel pathogenic
IL-17 production. Remarkably, similar association has been
recently described for Candida albicans, which is a potent
IL-23/Th17 inducer too (17). Some other new mechanisms
in PSO relating CLA+ T cells and IL-17 have been recently
revealed. The cytokine milieu present in psoriatic lesions can
influence IL-17 response by CLA+ T cells. IL-15 and IL-23, both
present in psoriatic lesions, have been shown to synergize with
CLA+ T cells and autologous epidermal cells to produce IL-
17A and IL-17F in PSO. This phenomenon occurs without the
use of any exogenous stimulus, in a major histocompatibility
complex (MHC)-dependent way, and independently of resident
T cells (18), but it does not take place using CLA− T cells
or cells from healthy controls. This is an example of how
psoriatic skin cytokine microenvironment interacts specifically
with skin-related memory T cells generating the IL-17 response
critical for PSO initiation and maintenance. IL-9 is another
cytokine studied in the context of CLA+ T cells function in
PSO in the ex vivo coculture model with autologous epidermal
cells (19). Streptococcus pyogenes preferentially triggers IL-9 in
CLA+ T cells together with other mediators such IL-17A. In
contrast to the previous studies where IL-9 is not induced by
natural stimulus, IL-9 is produced in a time-dependent way and
not transiently. Interestingly, the neutralization of S. pyogenes-
induced IL-9 by CLA+ T cells decreased IL-17A production
by 50%.
Furthermore, the descriptive analysis of T cell subpopulations
in patients with PSO revealed differential role for CD4+ and
CD8+ T lymphocytes, whereas CLA expression is associated
with skin recruitment of CD4+ central memory T cells (TCM),
particularly those CCR4+ and CCR6+, suggesting a specific role
for these cells in patrolling the skin compartment; CD8+ T
cells are more likely to accumulate in psoriatic skin and stay as
resident memory T cells (TRM) (20). Still, there is a need for
psoriatic models, closely representing human disease, to be used
as drug screening platforms. Recently, Shin et al. (21) developed
psoriatic human 3D skin constructs (pHSCs) by incorporating
T cells, over the classical approach based on the use of patient-
derived keratinocytes or fibroblasts treated with PSO-related
cytokines. As lymphocyte source, they tested in vitro polarized
Th1/Th17 cells and CCR6+ CLA+ T cells from the patients with
PSO, both of which showed psoriatic phenotype on epidermal
cells along with disease-associated cytokine profile. Interestingly,
when different psoriatic drugs were tested, those pHSCs with
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FIGURE 1 | Translational relevance of human circulating memory CLA+ T cells in inflammatory skin disorders. (A) In skin-draining lymph nodes, antigen-specific
Langerhans cells encounter naïve T cells generating memory T cells that express the skin-homing receptor CLA. CLA+ memory T cells enter the general circulation,
through efferent lymphatic vessels, and will extravase to inflamed skin. Some CLA+ memory T cells leave cutaneous tissue through afferent lymphatic vessels,
(Continued)
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FIGURE 1 | Recirculating back to the bloodstream, whereas, others are retained at the epidermal layer as resident memory T cells. (B) Principal
antigen/allergen/autoantigen-induced effector functions of CLA+ memory T cells in human inflammatory cutaneous conditions. AA, alopecia areata; ACD, allergic
contact dermatitis; AD, atopic dermatitis; CLA, cutaneous-associated lymphoid antigen; CLP, cutaneous lichen planus; DRESS, drug rash with eosinophilia and
systemic symptoms; LC, Langerhans cells; OLP, oral lichen planus; PSO, psoriasis; TRM, T-resident memory. This figure was created using images from Smart Servier
(https://creativecommons.org/licenses/by/3.0/), WikiHow (https://creativecommons.org/licenses/by-nc-sa/3.0/) and Freepik.es (@brgf).
CCR6+ CLA+ T cells responded differently to the ones with
in vitro polarized Th1/Th17 cells, highlighting the relevance of
using patient-CLA+ T cells to better address and even anticipate
specific therapeutical responses in vitro, moving one step forward
to personalized medicine in PSO field.
The CLA+ lymphocytes have been extensively studied in
the context of PSO disease, as last reviewed here (22). The
importance of CLA+ T cells in PSO resides not only in their
contribution to lesion formation but also in their role as
peripheral biomarkers of successful treatment, as it has been
confirmed by recent studies. For example, a significant reduction
of circulating CLA+ T cell, as well as IL-6 and IL-22, has
been associated with clinical efficacy after anti-tumor necrosis
factor (TNF)-alpha treatment (23). Similarly, a reduction on
the number of CLA+ Th17/Tc17 and Th22/Tc22 cells was
observed after 6 weeks of phototherapy and balneotherapy, which
positively correlated with the reduction on PSO area and severity
index (PASI) score (24).
ATOPIC DERMATITIS
The CLA+ T cells are involved in initiation and perpetuation
of AD (25), as they are functionally related to cutaneous
inflammation (4, 26). Recent blood phenotyping studies on
peripheral blood mononuclear cells from patients with AD and
healthy controls (HC) have illustrated increased percentage of
CLA+ memory T cells in moderate-to-severe patients with AD
compared with age-matched HC, but a decrease with increasing
age only in patients with AD (27, 28). The expansion of CLA+
T cells is accompanied by predominance of CLA+ Th2/Tc2 and
Th22/Tc22 response in AD. Although CLA+ Th2 cell counts are
similarly increased across all ages and are significantly higher
than HC, CLA+ Th22 cell counts increase with age only in
AD and its levels are also higher than that in HC (27–29).
CLA+ Th22 levels correlate with severity parameters [scoring
atopic dermatitis (SCORAD) and eczema area and severity
index], pruritus, and IL-17-producing cells (29, 30). CLA+ IL-
13+ T cells positively correlate with SCORAD, serum IgE levels,
and IL-22 frequencies (27). Regarding Th1/Tc1 cell subsets,
AD is characterized by decreased CLA+ Th1/Tc1 frequencies
in conjunction with negative correlations between CLA+ IFN-
gamma+ T cells and SCORAD, and CLA+ IL-13+ and IL-22+
populations. CLA+ Th1 frequencies increase with age both in AD
and HC, but do not reach the HC levels, and they are associated
with disease duration. All these data support an imbalanced
CLA+ Th1:Th2 cell ratio that increases with age both in AD and
HC, but remains decreased in AD (27–29).
The expression of the indicator of T cell mid activation,
inducible costimulatory molecule (ICOS), has been reported
to be enhanced both in CLA+ and CLA− memory T cell
subsets in patients with AD compared to HC and patients with
PSO, predominantly in the skin-homing subset, and correlates
with SCORAD. In contrast, the expression of human leukocyte
antigen (HLA)-DR, the chronic T cell activation MHC class II
antigen, is similar in infants regardless AD status, but increases
with age reaching high levels in adult patients with AD vs.
HC and patients with PSO, particularly among CLA+ T cell
population, which correlates with SCORAD (28, 29, 31). Besides,
frequencies of CLA+ regulatory T cells (Tregs) are higher in AD
compared with HC and patients with PSO, and they correlate
with both ICOS and HLA-DR, and also with clinical parameters
(SCORAD and IgE levels) (31). Intriguingly, OX40, another
costimulatory molecule predominantly expressed on T cells and
required for long-term memory responses, is mainly expressed
by CLA+ memory T cells in both patients with AD and HC
(32). A recent epigenetic report has extended the knowledge
on the CLA+ T cells of male adult patients with severe AD
and allergen-specific IgE sensitization (33). Peripheral blood
mononuclear cells sorted into four different T cell populations
(CD8+, CD4+, CD4+ CD45RA+, and CD4+ CLA+) have
revealed differentially DNA methylations in 40 protein-coding
genes in the CD4+ CLA+ subset in patients with AD vs. HC.
Among them, IL-13 gene promoter shows decreased methylation
levels, which negatively correlate with IL13 mRNA expression
levels in this subset.
VITILIGO
Melanocyte-specific circulating memory CD8+ CLA+ T cells
induce melanocyte apoptosis, together with other mechanisms,
such as cell detachment triggered by E-cadherin disruption
(34), contribute to melanocyte loss and the development of
depigmented skin lesions in vitiligo. Several blood endotyping
studies have depicted that patients with vitiligo have low
frequencies of circulating CD4+/CD8+ CLA+ TEM/TCM cells
compared to patients with PSO, being similar to HC, supporting
that CLA+ T cells migrate to the skin (35, 36). Within T cell
subsets, patients with vitiligo have the highest frequency of
CD4+/CD8+ CLA+ T cells producing IFN-gamma compared
with patients with AD, PSO, and alopecia areata (AA), and HC
(35), supporting that vitiligo is caused by a type 1 T cell response
(37, 38). Consistent with the literature describing CD8+ T cell
role in melanocytes death under IFN-gamma stimulation, CD8+
CLA+ T cell population producing IFN-gamma predominates
over CD4+ CLA+ T cell subset in patients with vitiligo (35).
Interestingly, the same study showed the highest frequency of
CD4+/CD8+ CLA+ T cells producing IL-9 in patients with
vitiligo in comparison with patients with AD, PSO, and AA
and HC, pointing out for the first time a possible role for IL-
9 on the physiopathology of vitiligo. Furthermore, Th17 subset,
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either CLA+ or CLA−, was also increased in vitiligo compared
to patients with HC, AD and, surprisingly, with PSO, a disease
associated to be driven by IL-17 activation. Regarding CLA+
Th22 subset, it was also augmented in patients with vitiligo
compared to patients with PSO and HC (35). In accordance
to this fact, IL-22 has been reported to participate in the
pathogenesis of vitiligo, as it promotes IL-1β secretion from
keratinocytes what cause the suppression of melanogenesis and
melanocyte migration as well as the induction of melanocyte
apoptosis (39). The active participation of autoreactive CD8+
T cells in vitiligo indicates that immune tolerance has been
disrupted. Several studies have shown that patients with vitiligo
have a reduced amount of infiltrating Tregs in non-lesional,
perilesional, and lesional skin (40, 41). Patients with vitiligo
also have fewer amounts of total circulating Tregs compared to
patients with AD and PSO, the difference being not that obvious
in the CLA+ Tregs subset (35).
ALOPECIA AREATA
The CLA relevance in AA in humans was first revealed by
Yano et al. (42), describing higher positivity in peripheral blood
mononuclear cells, CD4+ and CD8+ lymphocytes from AA
compared with HC, and that CLA positivity negatively correlated
with clinical improvement. Later, phenotyping research on
peripheral blood mononuclear cells described that CLA+/− Th2-
cell frequencies are similar between patients with AA and AD,
both higher than HC, and they correlate with AA severity;
however, skin-homing Tc2 and Th22 are significantly higher
in AA vs. HC (43). Also, the positive correlations have been
reported not only between CLA+ Th2/Tc2 and Th22/Tc22 but
also between CLA+ Th17/Tc17 and Th22/Tc22, particularly in
the CD8+ subset. In addition to this, skin-homing CD4+/CD8+
TCM-cell counts are higher in patients with AA, compared with
HC and patients with AD, unlike CD4+/CD8+ TEM frequencies,
and CD4+, but not CD8+, subset shows HLA-DR activation
in TCM cells. Regarding Tregs cells, diminished frequencies of
total and CLA+ Tregs have been described in patients with AA
compared to HC and patients with AD, which correlate with
skin-homing Th9, Th2/Tc2, Tc17, and Tc22 counts.
OTHER INFLAMMATORY SKIN DISEASES
In lichen planus, there is an accumulation of CLA+ T cells in
the epithelium of the buccal mucosa in oral lichen planus (OLP),
and in the epidermis of skin biopsies in cutaneous lichen planus
(CLP) (44). Increased E-selectin expression in lesional biopsies
from OLP over perilesional tissue, together with a significantly
higher proportion of CD8+ CLA+ T cells were observed by
the immunohistochemical analysis. It has been shown cutaneous
T cell-attracting chemokine (CTACK, also CCL27) secretion
by oral keratinocytes, which increased in the presence of IFN-
gamma and actively attracted CLA+ memory T cells to the
oral epithelium. Although both normal oral mucosa and lesions
from chronic OLP showed low levels of CTACK expression,
it may still play a role in early recruitment of T cells and
immunopathogenesis of OLP (45).
Although the role of CLA+ T cells in non-immediate drug-
induced cutaneous reactions was first reported two decades ago
(46), there is still a lot to learn about them in drug allergy.
Recently, it has been shown that in drug rash with eosinophilia
and systemic symptoms (DRESS) (47), IL-4 and IL-13 producing
CD4+ T cells are increased during active disease and decline
with recovery, pointing at the relevance of CLA+ Th2 cells in
the pathogenesis of DRESS. In β-lactam hypersensitivity, a new
T cell subset has been proposed, in which blood- and skin-
derived clones specific for piperacillin expressed high levels of
skin-homing chemokine receptors and migrated in the presence
of the ligands CCL27 (48).
DISCUSSION
The involvement of CLA+ T cells in different inflammatory skin
disorders, with diverse pathological immunological mechanisms,
makes them interesting for human dermatology (Figure 1B).
Also, circulating memory CLA+ T cells specific for disease
relevant antigens/allergens have reported, for example, S.
pyogenes in PSO (22) or house dust mite and Staphylococcus
aureus enterotoxin B in AD (4). Despite the functional relevance
of memory CLA+ T cells has been better described in PSO and
AD (4, 22, 49); their potential role in other T cell-mediated skin
conditions is still to be fully investigated. Various approaches
that involve minimal manipulation of those cells are providing
immunological information that relates to clinic in a translational
way. Although animal models and complex in vitro models
are providing important information to understand human
inflammatory skin disorders, there is a need to use clinical human
samples to gather genetic background and real diseased skin
cells of patients (50). For example, animal models cannot reflect
the immune response present in patients after several years of
chronic cutaneous inflammation and numerous flares. Different
aspects can influence the immune response in inflammatory skin
diseases such as genetic background, disease endotype/patient
heterogeneity, local antigen presentation by human epidermal
cells, impact of environmental triggers of disease, or neurogenic
inflammation. This integrated view is the approach that CLA+ T
cells exploration follows.
Nonetheless, the interplay between circulating and tissue-
resident CLA+ T cells should be further addressed. Particularly
since the latter have been described to persist in resolved skin
after treatment and to be involved in the recurrence of cutaneous
lesions in PSO, vitiligo, or fixed drug eruptions (51).
We are clearly still at the top of the iceberg unraveling the
information that those lymphocytes can provide for human
inflammatory cutaneous conditions. For all these translational
capacities, circulating memory CLA+ T cells can be proposed
as peripheral cellular biomarkers in human inflammatory
skin disorders.
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